Cholesterol drug shows benefits for kidney patients

Nov 22, 2010

( -- A combination drug that lowers levels of 'bad' cholesterol in the blood can benefit people with chronic kidney disease and is safe, a study led by the Clinical Trial Service Unit at Oxford University has found.

Patients receiving the daily pill – a combination of simvastatin and ezetimibe produced by Merck – had one-sixth fewer heart attacks, strokes or operations to unblock arteries than those receiving a placebo ‘dummy’ pill. The study findings were reported at an American Society of Nephrology conference in Denver, USA.

Chronic kidney disease is very common, affecting up to one in twenty of the middle-aged population, and substantially more of those who are older. Although people with chronic kidney disease are known to have an increased risk of a stroke or heart attack, it has been very unclear what treatments could prevent these conditions in this group of patients.

Dr Martin Landray, co-principal investigator at Oxford’s Clinical Trial Service Unit, said: ‘Over the past couple of decades, we have increasingly recognized that chronic kidney disease is associated with a high risk of cardiovascular complications, and have realised that kidney disease is common. But we have failed so far to identify any treatments that are effective in reducing that risk.

‘The SHARP trial results now provide clear evidence that lowering with ezetimibe/simvastatin safely reduces the risk of major atherosclerotic events. This is the first trial that has demonstrated that the high risk of heart attacks, strokes and other vascular diseases can be reduced in these patients.’

The Study of Heart and Renal Protection (SHARP) involved almost 9,500 volunteers aged 40 or over with chronic kidney disease. Those taking part came from 380 hospitals in 18 countries and had lost more than 50% of their normal kidney function, with a third of them requiring dialysis treatment. None had had a previous heart attack or needed bypass surgery or ‘stents’ to unblock their heart arteries.

Volunteers in this double-blind placebo-controlled trial were randomly allocated to take either cholesterol-lowering therapy with a tablet containing ezetimibe 10mg daily and simvastatin 20mg daily, or matching placebo tablets. Study treatment and follow-up continued for an average of 5 years.

In that time, 11.3% of patients (526 out of 4650) taking the drug had a heart attack, stroke or needed an operation to unblock an artery compared with 13.4% (619 of 4620) in the placebo group. That’s a reduction of a sixth in the likelihood of these events.

Professor Colin Baigent of the Clinical Trial Service Unit at Oxford University, the trial’s principal investigator, said: ‘This is excellent news for patients who have kidney disease.

‘It was already known that cholesterol-lowering could reduce the risk of heart attacks, strokes and the need for surgery to unblock arteries in people with normal kidney function. But this trial now shows that cholesterol-lowering has similar effects in people with chronic kidney disease, irrespective of the severity of their illness.’

During the 5-year period of the trial, the proportion of patients who stopped taking their allocated treatment was about one third, but this was not generally due to side-effects and was the same for both real and dummy treatments. If taken without interruption, however, ezetimibe plus simvastatin could have even larger effects than were seen in SHARP, the researchers note. Taking ezetimibe plus simvastatin long-term could avoid around one quarter of heart attacks, strokes and operations to unblock arteries, leading to their prevention in at least 250,000 people with kidney disease worldwide each year.

Importantly there were no safety concerns with the drug, which is already being taken by many people with normal kidney function to lower their cholesterol.

There was no support for previous concerns with ezetimibe about possible adverse effects on cancer, and no evidence of an increased risk of muscle or liver problems.

Dr Landray said: ‘There was no evidence of any serious adverse effects and, in particular, no support for earlier concerns that ezetimibe might cause cancer. SHARP shows clearly that the large cholesterol reduction produced with this treatment is safe, and provides similar benefits to those seen in people with normal kidney function.’

The SHARP trial was designed, conducted and analysed independently of all funding sources by the Clinical Trial Service Unit at Oxford University, with guidance from an independent steering committee that included many of the world’s leading kidney specialists.

The study was supported by Merck (known as MSD outside the US and Canada), who also supplied the study tablets. Additional support came from the Australian National Health and Medical Research Council (NHMRC), the British Heart Foundation (BHF) and the UK Medical Research Council (MRC).

Merck now plans to seek regulatory approvals for the use of Vytorin (the commercial name for the drug in the US) in patients with , based on the results from the SHARP study.

Explore further: Philippines boosts MERS monitoring after UAE nurse scare

add to favorites email to friend print save as pdf

Related Stories

Major international study to test new heart disease drug

Nov 18, 2010

( -- A major international study to test whether a new type of cholesterol treatment can prevent coronary deaths and heart attacks will start in early 2011. The study will be coordinated by the ...

FDA to review Vytorin results

Jan 26, 2008

The U.S. Food and Drug Administration said it is conducting a review of the cholesterol drug Vytorin based on preliminary results from a recent study.

Recommended for you

US orders farms to report pig virus infections

Apr 18, 2014

The U.S. government is starting a new program to help monitor and possibly control the spread of a virus that has killed millions of pigs since showing up in the country last year.

Foreigner dies of MERS in Saudi

Apr 18, 2014

A foreigner has died after she contracted MERS in the Saudi capital, the health ministry said on announced Friday, bringing the nationwide death toll to 73.

Vietnam battles fatal measles outbreak

Apr 18, 2014

Vietnam is scrambling to contain a deadly outbreak of measles that has killed more than 100 people, mostly young children, and infected thousands more this year, the government said Friday.

New clues on tissue scarring in scleroderma

Apr 18, 2014

A discovery by Northwestern Medicine scientists could lead to potential new treatments for breaking the cycle of tissue scarring in people with scleroderma.

User comments : 0

More news stories

Treating depression in Parkinson's patients

A group of scientists from the University of Kentucky College of Medicine and the Sanders-Brown Center on Aging has found interesting new information in a study on depression and neuropsychological function in Parkinson's ...

Airbnb rental site raises $450 mn

Online lodging listings website Airbnb inked a $450 million funding deal with investors led by TPG, a source close to the matter said Friday.

Health care site flagged in Heartbleed review

People with accounts on the enrollment website for President Barack Obama's signature health care law are being told to change their passwords following an administration-wide review of the government's vulnerability to the ...